Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > biorun, you loser

<< Previous

Bullboard Posts

Next >>

Comment by biorunon Sep 29, 2022 5:06pm

128 Views

Post# 34996013

RE:RE:RE:RE:RE:RE:RE:RE:biorun, you loser

He said "the payments from the upfront AND milestones are significant" - that means that between the upfront and milestones (which are different from royalties which are % of sales), there is money. So that means that IF the upfront is lower than expectation, then it should be made up in the milestones.

As for milestones, I am not sure how that works, but I expect that it would possibly consider key performance indicators such as meeting manufacturing and market introduction moments. For instance, every new market they go into. Keep in mind this is a global agreement they have negotiated.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing